Sector
PharmaceuticalsOpen
₹206.2Prev. Close
₹226.5Turnover(Lac.)
₹13.38Day's High
₹225Day's Low
₹20652 Week's High
₹396.9552 Week's Low
₹167.25Book Value
₹29.09Face Value
₹10Mkt Cap (₹ Cr.)
265.73P/E
37.56EPS
6.03Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 13.71 | 10 | 10 | 8.5 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 14.19 | -13.07 | -17.58 | -53.39 |
Net Worth | 27.9 | -3.07 | -7.58 | -44.89 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 25.09 | 16.35 | 17.95 | 32.66 |
yoy growth (%) | 53.46 | -8.92 | -45.02 | -71.71 |
Raw materials | -14.8 | -9.06 | -25.38 | -28.15 |
As % of sales | 58.98 | 55.43 | 141.36 | 86.19 |
Employee costs | -2.49 | -2.61 | -2.96 | -2.77 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 1.41 | -1.8 | -53.37 | -26.41 |
Depreciation | -0.85 | -1.07 | -1.19 | -1.19 |
Tax paid | 0 | 0.1 | 0.31 | 0.19 |
Working capital | 2.96 | 8.78 | -54.83 | -23.02 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 53.46 | -8.92 | -45.02 | -71.71 |
Op profit growth | -744.32 | -99.36 | 124.45 | 321.48 |
EBIT growth | -233.46 | -97.82 | 144.81 | 251.42 |
Net profit growth | -183.08 | -96.78 | 102.35 | 79.09 |
Particulars (Rupees in Crores.) | Mar-2024 |
---|---|
Gross Sales | 54.41 |
Excise Duty | 0 |
Net Sales | 54.41 |
Other Operating Income | 0 |
Other Income | 0.52 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,766.2 | 134.52 | 4,23,770.54 | 1,181.05 | 0.76 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,958.35 | 76.3 | 1,58,175.47 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,486.75 | 25.8 | 1,20,075.94 | 1,438.15 | 0.87 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,183 | 59.05 | 1,07,722.35 | 485 | 0.88 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,434.1 | 51.93 | 1,00,425.74 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Ashwin Khemka
Independent Director
Mrunmai M Sarvankar
Independent Director
Monika Singhania
Executive Director
Srivardhan Ashwani Khemka
Independent Director
Abhay Shah
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Sanjivani Paranteral Ltd
Summary
Sanjivani Paranteral Ltd is a WHO-GMP certified core pharmaceutical company and a pioneer in the manufacturing of injectables and oral solids with an extensive experience spanning two-and-a-half-decades. The Company primarily focus on life-saving drugs and has exports to over 25 countries, while catering to the needs of a vast geographic area through two WHO-GMP certified manufacturing facilities in Mumbai and Dehradun.Incorporated as a public limited company in Oct.94, Sanjivani Parenteral was jointly promoted by Anami H Khemka and a team of professionals in various fields of pharmaceutical industry. The Company has been involved in the manufacturing of pharmaceutical medicines. The Companys products includes oral solids, small volume parenteral and sterile powder formulations.The company is setting up a plant at Taloja, Maharashtra, to manufacture high grade anti-biotics and life saving injectibles used in various infections, pre- and post-operative. The installed capacities for its products will be, 150 lac pa each for liquid vials and powder vials and 73 lac pa for its ampoules, taking the total capacity to 375 lac pa. The company came out with a public issue in Jan.96 to part-finance the project.The promoters have received firm inquiries from reputed pharmaceutical companies like Merind, Lupin Laboratories and USV for the first year production of liquid vials and ampules.During the year 1998-99, the Company has been approved by the WHO GMP Certificate. The Company is hop
Read More
The Sanjivani Paranteral Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹223.65 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sanjivani Paranteral Ltd is ₹265.73 Cr. as of 09 May ‘25
The PE and PB ratios of Sanjivani Paranteral Ltd is 37.56 and 7.78 as of 09 May ‘25
The 52-week high/low is the highest and lowest price at which a Sanjivani Paranteral Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Sanjivani Paranteral Ltd is ₹167.25 and ₹396.95 as of 09 May ‘25
Sanjivani Paranteral Ltd's CAGR for 5 Years at 102.82%, 3 Years at 66.64%, 1 Year at 23.53%, 6 Month at -27.85%, 3 Month at -24.44% and 1 Month at -4.41%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.